The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD, despite the availability of two highly efficacious approved therapies—Genentech’s Lucentis and Regeneron’s Eylea. These current therapies, all of which target vascular endothelial growth factor (VEGF) and have been shown to maintain and even improve visual acuity in wet AMD patients, compete directly for patient share. It is essential to understand the use of these agents in the nuanced wet AMD treatment algorithm ahead of anticipated product launches. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
- How have Lucentis, Avastin, and Eylea been integrated into the treatment algorithm, and what is their source of business?
- How do wet AMD patients progress through lines of therapy, and how long are they maintained on treatment before progressing?
- What percentage of wet AMD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- Are most recently treated wet AMD patients with each key brand coming through new (adds/switches) or continuing business?
- What are the product-level compliance and persistency rates among drug-treated patients with wet AMD?
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Lucentis, Avastin, Eylea, Visudyne, Macugen
Key analysis provided:
- Brand/therapy usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Dry And Wet Age-Related Macular Degeneration - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms Claims Data Analysis Wet AMD US February 2019
Author(s): Shefali Gulati, MBA Pharm; Emma McFadden, PhD
Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group.
She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.
Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy.
Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.